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Background: In Estonia, women have much longer life expectancy than men. The aim of this study was to
examine sex differences in cancer survival in Estonia and to explore the role of age at diagnosis, stage at diagnosis
and tumour subsite.
Methods: Using data from the population-based Estonian Cancer Registry, we examined the relative survival of
adult patients diagnosed with nine common cancers in Estonia in 1995–2006 and followed up through 2011. Excess
hazard ratios (EHR) of death associated with female gender adjusted for age, stage at diagnosis and tumour subsite
were estimated.
Results: A total of 20 828 male and 13 166 female cases were analysed. The main data quality indicators were
similar between men and women. Women had more cases with unknown extent of disease at diagnosis. Overall,
the age-adjusted 5-year relative survival ratio was higher among women than men for all studied sites, but the
difference was significant for cancers of mouth and pharynx (22% units), lung (5% units), skin melanoma (17% units)
and kidney (8% units). The increase in survival over time was larger for women than men for cancers of mouth and
pharynx, colon, rectum, kidney and skin melanoma. In multivariate analysis, women had a significantly lower EHR of
death within five years after diagnosis for five of the nine cancers studied (cancers of mouth and pharynx, stomach,
lung, skin melanoma and kidney). Adjustment for stage and subsite explained some, but not all of the women’s
advantage.
Conclusions: We found a significant female survival advantage in Estonia for cancers of mouth and pharynx,
stomach, lung, kidney and skin melanoma. The differences in favour of women tended to increase over time as
from the 1990s to the 2000s, survival improved more among women than among men. A large part of the
women’s advantage is likely attributable to biological factors, but other factors, such as co-morbidities, treatment
compliance or health behaviour, are also probable contributors to gender survival disparities in Estonia and merit
further investigation. Our findings have implications for public health, early detection and cancer care in Estonia.
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Women have a longer life expectancy than men; in 2012,
the difference between the life expectancy at birth of
women and men in Europe was 5.6 years (83.1 vs. 77.5
years, respectively) [1]. In Estonia, health disparities be-
tween sexes are even larger, as the life expectancy at birth
is 81 years for women, but only 73 years for men [2].
Among all causes of death, cancer ranks second after cir-
culatory diseases [3]. Globally, cancer mortality among* Correspondence: kaire.innos@tai.ee
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unless otherwise stated.men is much higher compared to women [4]. Mostly, this
difference mirrors sex differences in cancer incidence [5],
but many studies have also observed sex disparities in can-
cer survival [6,7]. As hypothesised elsewhere, a consider-
able part of gender differences in cancer survival likely
arises from inequalities in tumour biology, including host
defence mechanisms, while the factors such as health be-
haviour, awareness of symptoms, timeliness of diagnosis
and co-morbidity may also be important contributors to
gender disparities [8].
The aim of this study was to analyse gender differ-
ences in cancer survival in Estonia and to explore thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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site using data from the population-based Estonian Cancer
Registry (ECR). Cancer is a reportable disease in Estonia by
legislation. The registry covers the whole country (popula-
tion 1.34 million in 2009) and has population-based cancer
data since 1968 [9]. Estonian cancer data have been in-
cluded in the Cancer Incidence in Five Continents since
Volume VI (data from 1983).
Methods
The ECR provided individual data with no personal
identifiers on all adult (15 years and older) cases of nine
most common malignancies occurring in both genders,
diagnosed in Estonia in 1995–2006, regardless of cancer
sequence: mouth and pharynx (ICO-O-3 topography
codes C00–C14); stomach (C16), colon (C18), rectum,
rectosigmoid junction, anus (C19–C21), pancreas (C25),
lung, trachea (C33–C34), melanoma of skin (C44), kid-
ney, renal pelvis (C64–C65), bladder, ureter, other urin-
ary organs (C66–C68). The following quality indicators
were calculated: percentage microscopically verified
(%MV), percentage death certificate only (%DCO), per-
centage autopsy and percentage unknown extent of
disease. Cases diagnosed at autopsy and DCO cases were
excluded from survival analysis. The patients were
followed up for vital status until December 31, 2011 using
linkage with the Population Registry. This routine linkage
is based on unique personal identification numbers [10].
In case of death or emigration, the respective date was
ascertained. Relative survival was calculated as the ratio of
the observed survival of cancer patients and the expected
survival of the underlying general population. The latter
was calculated according to the Ederer II method using
national life tables for Estonian population stratified by
age, gender and calendar year. The patients were grouped
into five age categories: 15–44 years, 45–54 years, 55–64
years, 65–74 years, ≥75 years. The two youngest age
groups were collapsed for the modelling of excess mortal-
ity except for skin melanoma. Subsites according to ICD-
O-3 were considered for five cancers (mouth and pharynx,
stomach, colon, rectum, skin melanoma), for which sub-
site may be a prognostic factor based on a priori know-
ledge. Extent of disease was grouped into four categories
based on the information reported to the cancer registry:
1) localised; 2) local/regional spread (regional lymph nodes
or adjacent tissues); 3) distant (distant metastases or un-
specified advanced process); 4) unknown extent. For age
adjustment, we used the International Cancer Survival
Standards (ICSS) [11]. Age-adjusted relative survival ratios
(RSR) are presented for all patients and separately for pa-
tients diagnosed in 1995–2000 and 2001–2006.
The significance of the difference between proportions
was tested using a chi-square test. We estimated excess
hazard ratios (EHR) of death associated with femalegender within five years after diagnosis in the framework
of generalized linear models using a Poisson assumption
for the number of observed deaths [12]. Cases with un-
known extent of disease were excluded from these ana-
lyses. All models included year of follow-up and period
of diagnosis. The EHRs are presented with 95% confi-
dence intervals (95% CI). Interactions between year of
follow-up and stage or subsite were checked with likeli-
hood ratio test.
Stata 12 software was used for all analyses. The study
protocol was approved by the Tallinn Medical Research
Ethics Committee (decision no. 284).
Results
A total of 20 828 male and 13 166 female cases of nine
cancers sites were analysed. The differences between
men and women in the main data quality indicators
were generally small (Table 1). In both male and female
patients, %MV varied across cancer sites with the lowest
result for pancreas and lung. For the same sites, %DCO
exceeded 3% in both sexes. Skin melanoma had the
highest %MV and the lowest %DCO. Among cased diag-
nosed alive, the proportion of cases with unknown ex-
tent of disease was higher in women for all sites except
mouth and pharynx, and exceeded 5% for cancers of
pancreas, lung, stomach and bladder (only pancreas in
men). Female patients were older than male patients:
median age at diagnosis as well as the respective 75th
percentile was higher among women for all sites. Age
distribution by cancer site is shown in Table 2.
Subsite distribution varied between sexes for all five
cancers (Table 3). Stage distribution differed significantly
for cancers of mouth and pharynx, stomach, lung, kid-
ney and skin melanoma (Table 4).
Women had a significant survival advantage for can-
cers of mouth and pharynx, lung, skin melanoma and
kidney (Table 5). For these sites, women also experi-
enced superior survival in all age groups, although the
advantage was generally larger among younger patients
and statistically significant differences were seen only in
some age categories. For bladder cancer, women had
worse prognosis (non-significant) only among patients
younger than 55 years.
During the first period (1995–2000), the age-adjusted
five-year RSR was higher among women for all sites ex-
cept colon (Table 6); the women’s advantage was statisti-
cally significant for mouth and pharyngeal cancer (20%
units) and lung cancer (6% units), while it was borderline
significant for skin melanoma (14% units). During the sec-
ond period (2001–2006), the women’s advantage increased
to 24% units for cancer of mouth and pharynx and 19%
units for skin melanoma (both statistically significant). As
kidney cancer survival increased only among women, the
gender difference reached a significant difference of 13%


















1410 94.5 0.8 0.2 1.6 61 (54–68) 457 94.8 0.7 0.2 1.6 68 (57–76)
Stomach 3003 90.0 1.7 1.8 3.6 67 (58–73) 2505 88.5 2.4 1.3 5.3 71 (61–77)
Colon 2029 91.4 1.4 1.3 2.7 69 (62–75) 2789 88.5 1.2 1.6 3.9 72 (64–78)
Rectum 1627 93.6 1.0 0.5 2.6 68 (61–74) 1622 90.2 1.5 0.9 3.7 71 (63–78)
Pancreas 1235 53.7 3.1 4.5 6.1 66 (58–73) 1099 47.3 3.6 2.2 7.5 72 (64–79)
Lung 7442 73.6 3.5 3.2 4.3 66 (60–72) 1771 66.9 3.4 3.6 5.8 70 (62–76)
Skin
melanoma
539 98.5 0.7 0.2 2.8 62 (51–71) 980 99.1 0.2 0.3 3.0 64 (49–73)
Kidney 1742 81.2 1.8 4.7 2.5 64 (56–71) 1255 80.1 1.0 3.2 4.0 68 (60–75)
Bladder 1801 94.0 1.2 1.0 4.0 69 (63–76) 688 90.0 2.8 1.5 5.5 74 (67–80)
Abbreviations: %MV percentage microscopically verified, %DCO percentage death certificate only, IQR interquartile range.
*Among cases diagnosed alive and eligible for survival analysis.
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unit significant difference persisted throughout the study
period. The increase in survival over time was much larger
for women than men for both colon and rectal cancers.
Women had a significantly lower EHR of death within
five years of diagnosis for five of the nine cancers studied
(cancers of mouth and pharynx, stomach, lung, skin
melanoma and kidney) (Table 7). In age-adjusted ana-
lyses, women had almost 50% lower EHR of dying com-
pared to men for cancers of mouth and pharynx and
skin melanoma. Adjustment for stage and subsite ex-
plained some of the women’s advantage, but a significant
portion of this advantage remained unexplained. For
stomach cancer, women had 10% lower EHR of death
and the inclusion of stage and subsite into the model did
not change the estimates. For cancers of lung and kid-
ney, women still had around 20% lower EHR of dying
compared to men after adjustment for stage. We ob-
served no survival differences between men and women
in any of the models for cancers of colon, rectum, pan-
creas and bladder.
We found evidence of interaction between year of
follow-up and extent of disease (stomach, rectum, pan-
creas, lung melanoma, kidney and bladder) or year of
follow-up and age (stomach, colon, rectum, lung, blad-
der); however, including the interaction term in the
model did not change the risk estimates for gender, and
therefore, these results are not shown.
Discussion
In this study based on data from the population-based can-
cer registry of Estonia, we found that women had a signifi-
cant survival advantage for five of the nine common solid
tumours included in the study. The direction and magni-
tude of the effect found in our study is consistent with thefindings of the analysis of EUROCARE-4 data for cancers
of mouth and pharynx, stomach, lung, and skin melanoma
[6]. For kidney cancer, the women’s advantage observed in
our study was much larger than in the European pool.
Unlike the EUROCARE-4 analysis, we did not find female
survival advantage for cancers of colon, rectum and pan-
creas. For bladder cancer, we found no gender differences
in survival whilst a significant female disadvantage was
seen in the EUROCARE-4 analysis.
Age is a major determinant of survival [13]. We
found that for most cancers, the gender difference in
survival varied across age categories; for many sites, the
women’s advantage was more marked in younger age
groups. It has been suggested that in this context, age
is a proxy for biological factors, particularly profound
hormonal changes that occur in women around the age
of menopause [6]. On the other hand, in younger and
middle-aged men free testosterone is hypothesised to
drive cancer aggressiveness [14].
The main strength of the study was the use of good-
quality population-based data, collected uniformly over
the study period. The quality of the ECR has remained
relatively stable from 1995 to 2008 with low %DCO and
percentage primary site uncertain [15]. In this study, we
found that the main quality indicators did not vary not-
ably by sex for any cancer site. Nevertheless, female pa-
tients were generally older than male patients, with
about 2-fold higher proportion of the age group 75 years
and older for some cancers (mouth and pharynx, pan-
creas and bladder). This was probably the main reason
for the somewhat higher proportion of cases with un-
known extent of disease observed among women com-
pared with men. As an additional strength of the study,
we were able to account for two major determinants of
survival – cancer subsite and extent of disease.
Table 2 Age distribution among cancer cases eligible for
survival analysis, Estonia, 1995–2006
No. of cases (%)
Cancer site Age at diagnosis
(years)
Men Women p-value*
Mouth, pharynx <45 76 (5) 35 (8) p < 0.001
45–54 317 (23) 60 (13)
55–64 503 (36) 92 (20)
65–74 379 (27) 128 (28)
≥75 120 (9) 136 (30)
Stomach <45 140 (5) 126 (5) p < 0.001
45–54 377 (13) 248 (10)
55–64 756 (26) 440 (18)
65–74 1067 (37) 801 (33)
≥75 557 (19) 797 (33)
Colon <45 54 (3) 73 (3) p < 0.001
45–54 159 (8) 183 (7)
55–64 456 (23) 498 (18)
65–74 809 (41) 970 (36)
≥75 496 (25) 988 (36)
Rectum <45 44 (3) 56 (4) p < 0.001
45–54 134 (8) 131 (8)
55–64 428 (27) 307 (19)
65–74 641 (40) 531 (34)
≥75 356 (22) 227 (35)
Pancreas <45 56 (5) 20 (2) p < 0.001
45–54 18 (13) 76 (7)
55–64 318 (28) 184 (18)
65–74 414 (36) 350 (34)
≥75 206 (18) 405 (39)
Lung <45 132 (2) 43 (3) p < 0.001
45–54 785 (11) 159 (10)
55–64 2131 (31) 334 (20)
65–74 2859 (41) 610 (37)
≥75 1041 (15) 501 (30)
Skin melanoma <45 98 (18) 188 (19) p = 0.076
45–54 75 (14) 147 (15)
55–64 130 (24) 199 (20)
65–74 147 (28) 239 (25)
≥75 83 (16) 199 (20)
Kidney <45 86 (5) 38 (3) p < 0.001
45–54 286 (18) 130 (11)
55–64 472 (29) 302 (25)
65–74 544 (34) 433 (36)
≥75 229 (14) 290 (24)
Table 2 Age distribution among cancer cases eligible for
survival analysis, Estonia, 1995–2006 (Continued)
Bladder <45 45 (3) 18 (3) p < 0.001
45–54 137 (8) 33 (5)
55–64 388 (22) 86 (13)
65–74 702 (40) 212 (32)
≥75 488 (28) 310 (47)
*Chi-squared test.
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examine the role of determinants of survival other that
age, stage and subsite, such as co-morbidities, health be-
haviour or factors associated with tumour biology. The
extent of disease at diagnosis as reported to the ECR is
not as precise as TNM stage and some misclassification
is possible. Misclassification of cancer subsite needs to
be considered as well. However, we do not expect any of
the misclassifications to be associated with gender. Rela-
tive survival compensates for general background mor-
tality; nevertheless, for patients with tobacco-related
cancers, relative survival may be underestimated because
their mortality from other diseases such as cardiovascu-
lar diseases is higher than in the general population. The
prevalence of smoking in men is higher than in women:
according to the biannual Estonian Health Behaviour
study, the prevalence of daily smokers in men age 15–64
years decreased from 45% in 1996 to 36% in 2012 (from
32% to 26% in women) [16]. Thus, some of the male dis-
advantage might be due to increased background mor-
tality from smoking-related co-morbidities.
Among oropharyngeal cancers, tongue and oral cavity
was the most common subsite for both genders, ac-
counting for 2/5 of the cases. The second most frequent
subsite was pharynx among men (ICD-O-3 C09–C13),
but salivary gland (ICD-O-3 C07–C08) among women.
Based on the EUROCARE study, the summary age-
adjusted 5-year RSR was significantly higher for cancers
of salivary glands than pharynx (especially hypopharynx)
[13]. Pharyngeal subsites were associated with consider-
ably higher excess risk of dying compared with subsites
within oral cavity in an analysis of head and neck can-
cers in Europe [17]. Thus, different proportions of these
subsites can contribute by itself to survival advantage
among women. Our results showed that the women’s
survival advantage was rather constant over the age-
span and only slightly decreased after the age of 65
years. In women, the improvement of 5-year RSR from
1995–2000 to 2001–2006 was more rapid compared to
men, and as a result, the gender difference increased.
Women also had more favourable stage distribution
(higher proportion of localised disease). In multivariate
analysis, however, considerable women’s survival advan-
tage persisted even after adjustment for age, stage and
Table 3 Subsite distribution among cancer cases eligible for survival analysis, Estonia, 1995–2006
No of cases (%)
Cancer site Subsite ICD-O-3 Men Women p-value*
Mouth, pharynx All C00–14 1395 (100) 451 (100) p < 0.001
Lip C00 158 (11) 77 (17)
Tongue and oral cavity C01–06 591 (42) 203 (45)
Salivary glands C07–08 95 (7) 96 (21)
Pharynx C09–13 529 (38) 70 (16)
Other ill-defined sites C14 22 (2) 5 (1)
Stomach All C16 2897 (100) 2412 (100) p < 0.001
Cardia C16.0 249 (9) 136 (6)
Non-cardia C16.1–16.4 1553 (54) 1308 (54)
Other C16.5–16.8 238 (8) 223 (9)
Unspecified C16.9 857 (29) 745 (31)
Colon All C18 1974 (100) 2712 (100) p < 0.001
Right C18.0–18.3 630 (32) 1055 (39)
Transverse C18.4 181 (9) 308 (11)
Left C18.5–18.7 1089 (55) 1263 (47)
Overlapping C18.8 38 (2) 29 (1)
Unspecified C18.9 36 (2) 57 (2)
Rectum All C19–21 1603 (100) 1582 (100) p < 0.001
Rectosigmoid junction C19 234 (14) 253 (16)
Rectum C20 1326 (83) 1229 (78)
Anus, anal canal C21 43 (3) 100 (6)
Skin melanoma All C44 533 (100) 972 (100) p < 0.001
Head and neck C44.0–44.4 74 (14) 133 (14)
Trunk C44.5 280 (52) 280 (29)
Upper limbs C44.6 54 (10) 147 (15)
Lower limbs C44.7 78 (15) 352 (36)
Overlapping, unspecified C44.8–44.9 47 (9) 60 (6)
*Chi-squared test.
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ence survival [18]. Co-morbidities, treatment compliance
and health behaviour after diagnosis may also play a role,
taking into consideration the major risk factors for these
cancers, particularly smoking and alcohol consumption.
Head and neck cancers associated with human papillo-
mavirus (HPV) have better survival than HPV-negative
tumours, which are mainly alcohol- or tobacco-related
[19], but no data are available regarding the HPV preva-
lence in oropharyngeal tumours in Estonia.
For stomach cancer, we observed a 3–4% unit female
survival advantage, similar to that found in Germany
and US [20]. Women had 10% lower EHR of dying,
which was not influenced by stage or subsite distribu-
tion. The analysis of EUROCARE-4 data demonstrated a
similar female survival advantage [6]. In the Austrian
study, women still had a survival advantage in an age-and stage-adjusted model [21], while in Korea, women’s
higher risk of death disappeared after adjusting for age
and stage [22]. Several underlying mechanisms have
been proposed for the protective effect of oestrogens
against gastric cancer [23]. The presence of oestrogen
receptors could protect against invasiveness of stomach
cancer [24], but their prognostic role may be limited
[25]. Body mass index (BMI) could be important in sur-
gical outcomes, especially in men: male patients with
high BMI were shown to have longer duration of oper-
ation and larger extent of bleeding compared to patients
with lower BMI; no such difference was seen among fe-
male patients [26].
In contrast to some previous studies [5,6,27], we did
not find female survival advantage for colon and rectum
cancers. The reasons for this are not clear. There was a
slight tendency towards female advantage during the
Table 4 Stage distribution among cancer cases eligible
for survival analysis, Estonia, 1995–2006
No. of cases (%)
Cancer site Extent Men Women p-value*
Mouth,
pharynx
All 1395 (100) 451 (100) p < 0.001
Localized 564 (40) 256 (57)
Local/regional
spread
752 (54) 169 (37)
Distant 57 (4) 19 (4)
Unknown 22 (2) 7 (2)
Stomach All 2897 (100) 2412 (100) p < 0.001
Localized 650 (22) 616 (26)
Local/regional
spread
739 (26) 579 (24)
Distant 1404 (48) 1090 (45)
Unknown 104 (4) 127 (5)
Colon All 1974 (100) 2712 (100) p = 0.048
Localized 787 (40) 1039 (38)
Local/regional
spread
509 (26) 748 (28)
Distant 625 (32) 819 (30)
Unknown 53 (3) 106 (4)
Rectum All 1603 (100) 1582 (100) p = 0.099
Localized 681 (42) 637 (40)
Local/regional
spread
449 (28) 479 (30)
Distant 432 (27) 407 (26)
Unknown 41 (3) 59 (4)
Pancreas All 1142 (100) 1035 (100) p = 0.114
Localized 117 (10) 132 (13)
Local/regional
spread
271 (24) 245 (24)
Distant 684 (60) 580 (56)
Unknown 70 (6) 78 (7)
Lung All 6948 (100) 1647 (100) p = 0.003
Localized 1127 (16) 285 (17)
Local/regional
spread
2676 (39) 567 (34)
Distant 2846 (41) 699 (42)
Unknown 299 (4) 96 (6)
Skin
melanoma
All 533 (100) 972 (100) p < 0.001
Localized 360 (68) 761 (78)
Local/regional
spread
98 (18) 108 (11)
Distant 60 (11) 74 (8)
Unknown 15 (3) 29 (3)
Table 4 Stage distribution among cancer cases eligible
for survival analysis, Estonia, 1995–2006 (Continued)
Kidney All 1617 (100) 1193 (100) p < 0.001
Localized 876 (54) 728 (61)
Local/regional
spread
228 (14) 145 (12)
Distant 473 (29) 272 (23)
Unknown 40 (3) 48 (4)
Bladder All 1760 (100) 659 (100) p = 0.299
Localized 1325 (75) 486 (74)
Local/regional
spread
213 (12) 87 (13)
Distant 152 (9) 50 (8)
Unknown 70 (4) 36 (5)
*Chi-squared test.
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stage distributions did not differ between men and
women in our study. For colon cancer, there was left
predominance of colon cancer among men and right-
transverse predominance among women; this pattern
has been observed previously [27]. Several previous
studies found that the women’s advantage was age-
related. For example, in the EUROCARE analysis, the
women’s advantage was much larger in the age group
15–54 years [6] and in a SEER-based study, women had
better survival than men until the age of 64 years [28].
In Germany, female advantage was most notable in
younger-middle ages and the advantage varied by stage
of CRC (larger for localised cancers) [27]. We did not
find any age-related patterns in survival differences, pos-
sibly due to small numbers in younger age groups.
Women had 6% units higher 5-year RSR for lung can-
cer in both periods, but the largest difference (13% units)
was seen amongst patients younger than 55 years of age.
In the EUROCARE-4-based study, a significant differ-
ence between the age-specific relative survival of men
and women was seen only among patients younger than
65 years [6]. After adjusting for age and stage, women in
our study had nearly 20% lower EHR of dying than men.
This estimate is very close to that found in an Austrian
study after similar adjustment [21]. The proportion of
small-cell lung cancer was 16% in both men and women;
women had a higher proportion of adenocarcinomas
and men had more squamous cell carcinomas, but the
inclusion of this variable into the model had no consid-
erable effect on the EHR of dying (data not shown). In a
Dutch study, men with lung cancer had higher preva-
lence of co-morbid conditions than women; it was also
shown that patients with co-morbidities (particularly the
elderly) were treated less aggressively [29]. On the other
hand, a SEER-based study of treated and untreated eld-
erly patients suggested a different natural history and
Table 5 Five-year relative survival ratios (RSR) in Estonia, women (W) and men (M), 1995–2006
All ages
(age-adjusted)



























































52 30 22* 62 31 31* 55 26 29* 54 22 32* 48 37 11 51 30 21
Stomach 23 20 3 26 31 −5 29 22 7 28 24 4 23 18 5 16 16 0
Colon 51 50 1 58 60 −2 52 53 −1 52 47 5 52 52 0 46 46 0
Rectum 46 42 4 42 42 0 53 41 12 53 50 3 49 48 1 34 31 3
Pancreas 6 5 1 15 17 −2 12 5 7 5 6 −1 5 2 3 3 5 −2
Lung 14 9 5* 28 15 13 23 10 13* 15 10 5 9 8 1 11 6 5
Skin
melanoma
73 56 17* 82 66 16* 75 60 15 69 51 18* 71 60 11 64 36 28
Kidney 62 54 8* 82 64 18 77 56 21* 69 58 11* 56 56 0 51 45 6
Bladder 65 63 2 78 88 −10 72 80 −8 73 66 7 67 60 7 50 50 0
*Significant difference at the 0.05 level.
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women [30]. In addition, genetic and hormonal have
been proposed as a potential explanation for the survival
benefit experienced by women [31].
The absolute difference between the 5-year RSR of
male and female melanoma patients increased from 14%
units to 19% units from 1995–2000 to 2001–2006 as
survival did not improve in men. The 5-year RSR for
women in Estonia in 2001–2006 was 12% units lower
than the European mean for 2000–2007 reported in
EUROCARE-5 (75% vs. 87%), but the respective differ-
ence among men was as much as 23% units (56% vs.
79%) [13]. We found female advantage in all age groups
in our study, with a particularly large difference among
patients age 75 years and over. The predominant subsite
was trunk among men, but lower limbs among women.Table 6 Age-adjusted five-year relative survival ratios (RSR) in
Men Wome
5-year RSR (95% CI) 5-year
Cancer site 1995–2000 2001–2006 1995–
Mouth, pharynx 28 (22–34) 32 (26–37) 48 (40–
Stomach 20 (18–23) 20 (18–23) 23 (20–
Colon 52 (47–57) 47 (43–51) 49 (46–
Rectum 38 (33–42) 46 (42–50) 39 (35–
Pancreas 5 (3–8) 4 (3–7) 7 (4–10
Lung 7 (6–9) 10 (9–12) 13 (10–
Skin melanoma 58 (50–66) 56 (49–62) 72 (66–
Kidney 54 (48–60) 54 (49–59) 58 (52–
Bladder 62 (57–67) 63 (59–67) 64 (57–
*Five-year RSR among women minus respective RSR among men.
**Significant difference at the 0.05 level.Women were more likely to have localised melanoma.
In age-adjusted analysis, female patients had almost 50%
lower EHR of death and this is consistent with the re-
sults of the analysis on the European pool [6]. Although
men were more likely to have melanomas with un-
favourable characteristics, such as location on the trunk
and more advanced stage at diagnosis, these factors did
not fully explain the women’s survival advantage. In a
large Dutch population-based study, men were nearly
twice as likely to die from their melanoma compared
with females after adjusting for a number of patient and
tumour characteristics such as age, region, Breslow
thickness, histology, body site as well as nodal and meta-
static status [32]. In a Finnish study, male patients had
worse survival than females in all site groups [33]. The
persistent female survival advantage among cases withEstonia, 1995–2006
n




56) 56 (48–63) 20** 24**
25) 24 (21–27) 3 4
52) 53 (49–56) −3 6
43) 52 (48–56) 1 6
) 4 (3–7) 2 0
16) 16 (13–19) 6** 6**
76) 75 (70–79) 14 19**
62) 67 (62–71) 4 13**
70) 66 (59–72) 2 3
Table 7 Excess hazard ratio (EHR) of death within five years after diagnosis for women compared to men, Estonia,
1995–2006
Cancer site EHR (95% CI)* EHR adjusted for age
(95% CI)
EHR adjusted for age
and extent (95% CI)
EHR adjusted for age, extent
and subsite** (95% CI)
Mouth, pharynx 0.54 (0.46–0.63) 0.54 (0.46–0.64) 0.60 (0.51–0.71) 0.66 (0.56–0.78)
Stomach 0.92 (0.86–0.98) 0.88 (0.82–0.94) 0.90 (0.84–0.96) 0.91 (0.85–0.97)
Colon 1.05 (0.96–1.15) 1.01 (0.92–1.11) 1.10 (1.00–1.21) 1.09 (0.99–1.19)
Rectum 0.98 (0.88–1.10) 0.92 (0.83–1.03) 1.00 (0.90–1.11) 0.99 (0.89–1.10)
Pancreas 1.00 (0.91–1.09) 0.94 (0.85–1.03) 0.97 (0.88–1.06)
Lung 0.90 (0.85–0.96) 0.87 (0.82–0.93) 0.81 (0.76–0.86)
Skin melanoma 0.53 (0.43–0.66) 0.52 (0.43–0.64) 0.68 (0.55–0.84) 0.72 (0.58–0.90)
Kidney 0.76 (0.67–0.87) 0.72 (0.63–0.83) 0.81 (0.70–0.93)
Bladder 1.03 (0.86–1.24) 0.92 (0.77–1.11) 0.96 (0.80–1.15)
*All models include year of follow-up and period of diagnosis.
**Mouth, pharynx: lip (ICD–O–3 C00), oral cavity and tongue (C01-06), salivary glands (C07–08), pharynx and other (C09–14); Stomach: cardia (C16.0), non-cardia
(C16.1–16.4), other (C16.5–16.9); Colon: right (C18.0–18.3), transverse (C18.4), left (C18.5–18.7), other (C18.8–18.9); Rectum: rectosigmoid junction (C19), rectum
(C20), anus and anal canal (C21); Skin melanoma: head and neck (C44.0–44.4), trunk (C44.5), upper limbs (C44.6), lower limbs (C44.7), other (C44.8–44.9).
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immunological response to melanoma [32]. At the same
time, the unfavourable effect of lower socioeconomic sta-
tus on melanoma survival was also more pronounced
among men than among women [34].
Female kidney cancer patients had around 20% lower
EHR of dying than males in our study. This difference is
larger than seen in the EUROCARE-4 analysis [6]. The
5-year RSR for women in Estonia in 2001–2006 was 5%
units higher than the respective European mean in
EUROCARE-5 analysis (67% vs. 62%), but for men the
difference was 6% in favour of the European mean (54%
vs. 60%) [13]. Some previous studies have shown worse
survival for women [22] or no difference [21] while
many studies have reported women’s survival advantage
[35]. Kidney cancer survival improved over the study
period only among women in Estonia. Women showed
more favourable stage distribution which may be related
to the increasing use of modern abdominal imaging
techniques. Greater use of diagnostic imaging may result
in the diagnosis of more incidental renal cell carcinomas
among females than males and these tumours have bet-
ter prognosis compared with symptomatic tumours [35].
The comparison of age-specific RSRs revealed that
women’s significant survival advantage was limited to
patients under the age of 65 years.
Previous population-based studies have found poorer
outcomes for bladder cancer in women compared to
men [5,6,21,22]. We found non-significantly higher RSRs
for men among patients younger than 55 years, but
overall analysis did not reveal any differences. The male
advantage has been associated with different manage-
ment and referral practices [36,37]. In Estonia, women
visit doctors much more often than men; the proportion
of men who had visited a specialist physician during the
past year has been consistently about 18% units lowerthan that of women (33% vs. 51% in 2002 and 41% vs.
59% in 2012) [16].
Conclusions
The age-adjusted 5-year RSR was higher among women
than men for all nine cancer sites included in the study.
A statistically significant female advantage in the 5-year
RSR was seen for cancers of mouth and pharynx, lung,
kidney and skin melanoma. The differences in favour of
women tended to increase over time, as survival im-
proved more among women than among men over the
study period. For several sites, the survival gap between
the most recent estimates for Estonia and the rest of
Europe was much larger for men than for women.
Age was a significant contributor to gender survival
differences, but its role was not uniform across the can-
cer sites studied. For lung and kidney cancer, the
women’s advantage was largest before age 55 years, sug-
gesting the role of hormonal factors; for mouth and
pharyngeal cancer and melanoma, the advantage was
very large until age 65 and increased again in patients
age 75 years and older, suggesting the combined effect
of biological and social factors as well as co-morbidities.
For five sites (mouth and pharynx, stomach, lung, skin
melanoma and kidney), women had a significantly lower
EHR of dying in multivariate analysis that was not ex-
plained by age, stage or subsite.
A large part of the women’s advantage is likely attrib-
utable to biological factors, including hormonal status
or different molecular subtypes. The magnitude of the
women’s advantage observed in this study suggests that
the other factors, such as co-morbidities, treatment
compliance and/or health behaviour (including degree
of change in health behaviour after diagnosis) could be
contributors to gender disparities in Estonia and merit
further investigation using high-resolution approach.
Innos et al. BMC Cancer  (2015) 15:72 Page 9 of 9As some of these factors are modifiable, our findings
have implications for public health, early detection and
cancer care strategies in Estonia.
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